Experimental Drug Effectively Treats Alzheimer’s in Preclinical Study

NU-9 targets a shared underlying mechanism found in various neurodegenerative diseases. A new study from Northwestern University reports that NU-9, an experimental small-molecule drug currently approved by the U.S. Food and Drug Administration (FDA) for clinical trials in treating amyotrophic lateral sclerosis (ALS), also improves neuron health in animal models of Alzheimer’s disease. Both ALS [...]